Cost Effectiveness Analysis (CEA) of Bevacizumab (Bev) in 1st and 2nd-line treatment of metastatic colorectal cancer (mCRC)

ABSTRACT:

SUBMITTER:  

PROVIDER: S-EPMC4812840 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature